<DOC>
	<DOC>NCT00664599</DOC>
	<brief_summary>The purpose of this study is to find if Rituximab can improve severe ocular lesions of Behcet's Disease.</brief_summary>
	<brief_title>Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease</brief_title>
	<detailed_description>To test in a single blind randomized control study the efficacy of Rituximab versus combination of pulse cyclophosphamide and azathioprine. Both group receiving 0.5 mg/kg/daily prednisolone.</detailed_description>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Behcet's Disease fulfilling the new International Criteria for Behcet's Disease Having active ocular lesions (posterior and/or retinal vasculitis) Resistant to cytotoxic drugs + prednisolone 0.5 mg/kg Visual acuity less than 1/10 on Snellen chart Antecedent of allergic reaction to any component of the therapeutic regimen</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Ocular lesions, Visual Acuity, Retinal Vasculitis</keyword>
</DOC>